Offer - Urjas Oil for just ₹ 1 X
Relgin 0.5 Tablet is a prescription medicine that is available as a Tablet. It is typically used for the treatment of Parkinson's Disease.
The optimal dosage of Relgin 0.5 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
Apart from the aforementioned side effects, Relgin 0.5 Tablet can also lead to other problems, which have been listed below. Usually, these side effects of Relgin 0.5 Tablet go away soon, and do not persist beyond the duration of the treatment. If, however, they worsen or do not go away, please speak with your physician.
Furthermore, you should know that effect of Relgin 0.5 Tablet is Moderate for pregnant women and Severe for women who are breastfeeding. It is important to know if Relgin 0.5 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Relgin 0.5 Tablet related warnings section.
Individuals suffering from medical conditions like Psychosis, Low Blood Pressure (Hypotension) must refrain from the use of Relgin 0.5 Tablet since this can cause severe adverse effects. The section on Relgin 0.5 Tablet contraindications lists all such conditions.
Drug interactions for Relgin 0.5 Tablet have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for Relgin 0.5 Tablet, it is important to know that it is not safe while driving, and is not habit-forming.
Relgin 0.5 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Relgin 0.5 Tablet safe for pregnant women?
Relgin may have some side effects during pregnancy. Pregnant women should discontinue the use of Relgin, and talk to their doctor, if they notice any discomfort.
Is the use of Relgin 0.5 Tablet safe during breastfeeding?
Taking Relgin may lead to serious side effects if you are breastfeeding. Relgin should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Relgin 0.5 Tablet on the Kidneys?
Relgin rarely harms the kidneys.
What is the effect of Relgin 0.5 Tablet on the Liver?
Very few cases of side effects of Relgin on the liver have been reported.
What is the effect of Relgin 0.5 Tablet on the Heart?
Relgin is completely safe for the heart.
If you are suffering from any of the following diseases, you should not take Relgin 0.5 Tablet unless your doctor advises you to do so -
Is this Relgin 0.5 Tablet habit forming or addictive?
No, there is no any evidence that Relgin 0.5 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Relgin 0.5 Tablet as you may feel sleepy.
Is it safe?
Yes, Relgin 0.5 Tablet is safe for use.
Is it able to treat mental disorders?
Yes, Relgin 0.5 Tablet is useful in treating mental disorders.
Interaction between Food and Relgin 0.5 Tablet
Eating certain foods may increase the time it takes Relgin 0.5 Tablet to have an effect. You should consult your doctor about it.
Interaction between Alcohol and Relgin 0.5 Tablet
Taking alcohol with Relgin 0.5 Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Azilect (rasagiline mesylate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 432
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1085-1086